Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

The Worst Mistake Novavax Investors Can Make Right Now

By Jason Hawthorne - Jan 4, 2021 at 6:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors will soon have data to judge management's big projections.

Novavax ( NVAX -11.60% ) was in the perfect position to develop a COVID-19 vaccine, having previously succeeded against two similar coronaviruses (SARS and MERS) in the lab. The company chose a vaccine candidate in April, and nine months later, the phase 3 trial has finally begun in the U.S. In anticipation, the stock is up 660% over that time. It's not obvious what shareholders should do now, but there is something they shouldn't do.

An elderly woman getting a vaccine from a masked clinician.

Image source: Getty Images

Is all the good news already priced in?

Novavax became part of the U.S. government's Operation Warp Speed in July, and subsequently signed several deals with global vaccine manufacturers for a capacity of 2 billion doses per year, according to management. Despite several delays related to manufacturing, phase 3 data will be available by the end of April if the company follows the same timeline as Pfizer ( PFE -5.14% ) and Moderna ( MRNA -13.49% ). In the meantime, Novavax has a phase 3 study in the U.K. that could report out by early this quarter that should give insight about the company's future.

Although the company's vaccine has the advantage of using the traditional supply chain, there is a high bar to clear for relevance. Both Pfizer's and Moderna's vaccine demonstrated about 95% effectiveness in preventing COVID-19. Add in competition from companies selling their vaccine at cost, or others requiring only one shot, and the market for a coronavirus vaccine might get crowded quickly.

Novavax also has a flu vaccine that outperformed Sanofi's ( SNY 1.04% ) market leader in a phase 3 trial that ended in March, and management is exploring a combo shot of COVID-19 and influenza vaccine that would differentiate the product. That's in the future.

In the near term, the worst thing an investor could do is watch 2020's gains evaporate if the U.K. data isn't as positive as with other vaccines. Anyone with significant profits in Novavax shares may want to lock in gains on a portion of their investment and wait to see that the vaccine is effective and the company can successfully manufacture enough to meet its lofty projections. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$141.86 (-11.60%) $-18.62
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.48 (-5.14%) $-2.79
Sanofi Stock Quote
Sanofi
SNY
$47.56 (1.04%) $0.49
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$265.33 (-13.49%) $-41.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.